Aztreonam Data to Be Presented at European Cystic Fibrosis...
15.06.2005 / 16:59 / Rubriek: Informatief / Organisatie: Corus pharma
Aztreonam Data to Be Presented at European Cystic Fibrosis Society Conference
SEATTLE, June 15/PRNewswire/ --
- Data on Microbiology of an Investigational Inhaled Antibiotic for Cystic Fibrosis to Be Presented in Crete
Dr. Jane L. Burns will present Corus Pharma's Aztreonam Lysinate for Inhalation (AI) clinical Phase 2 microbiology results at the European Cystic Fibrosis Society Conference (ECFS) in Crete on Friday, June 24, 2005 at 5:00 p.m. EEST (Eastern European Summer Time) as part of a session on antibiotics and resistance.
WHO: Dr. Jane L. Burns and Corus Pharma
WHAT: Presentation of Corus Pharma's Aztreonam Lysinate for
Inhalation (AI) clinical Phase 2 microbiology results.
WHEN: Friday, June 24, 2005 at 5:00 p.m.
WHERE: Creta Maris, Crete (Athena room)
About The Phase 2 Results
The Phase 2 study was comprised of 105 cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa infections. It evaluated two dose groups (75 mg and 225 mg) with twice daily applications for two weeks in a double blinded, placebo-controlled trial.
Both dose levels were well tolerated with similar adverse event profiles as the placebo, though the 225 mg dose had a trend to increased respiratory symptoms (most commonly cough) when compared to either the 75 mg dose or placebo. There were no serious adverse events reported as related to AI.
There was a significant decrease in the amount of Pseudomonas aeruginosa as measured by sputum density with both dose groups showing greater than or equal to 97% reduction (greater than or equal to 1.5 log) from baseline (p (LESS THAN) 0.001). In patients with abnormal lung function at baseline, there was a significant improvement in FEV1 measured over the duration of the study (p (LESS THAN) 0.05).
Based on the Phase 2 results, Corus is currently enrolling patients in the AIR-CF Phase 3 clinical trials and more information can be found at www.AIR-CF.com. AI is delivered by the eFlow(R) Electronic Nebulizer developed by PARI GmbH with an average treatment time in Corus' Phase 2 clinical trial of 2.4 minutes for the 75mg dose.
About Dr. Jane L. Burns
Jane L. Burns, MD, is a Professor of Pediatrics at the University of Washington in Seattle, Washington. She is also Director of the Cystic Fibrosis Microbiology Laboratory and the Infectious Disease Clinic at Children's Hospital and Regional Medical Center, also in Seattle. Dr. Burns earned her medical degree from the University of Washington.
About Corus Pharma
Corus Pharma is committed to developing and commercializing products for severe respiratory and infectious diseases that can help provide improved health and quality of life. More information about Corus Pharma may be found at www.coruspharma.com.
Web site: www.coruspharma.com
Source: Corus Pharma
Jonathan Mow of Corus Pharma, +1-206-792-3020, or jmow@coruspharma.com; or Leslie Cohan of Dave Syferd & Partners, +1-206-262-0395, or cell, +1-206-849-1810, or lcohan@dsandp.com, for Corus Pharma